Subscribe to Newsletter
Outside the Lab Genetics and epigenetics, Profession, Omics

From Bench to Bedside and Back Again

What inspired you to study medicine – and what drew you to genetics?

As an undergraduate, I was interested in the physical sciences, and had planned on attending graduate school to do chemistry. However, my father and grandfather were both physicians, and I made the decision that if I was going to have a career in science, I wanted the results of my research to be closely connected to improving outcomes for patients. So I decided to enter a combined MD/PhD program at the University of Michigan.

My interest in genetics derived from my work as a young scientist and physician – my training really set the stage for my entire career. My motivation came from the interactions I had with patients during my research, as well as in my clinical rotations in pediatrics. I got to know three different patients who had really awful genetic diseases – a young man with Lesch–Nyhan syndrome, and one who had metachromatic leukodystrophy. The third patient – one who left a lasting impression on me – was a young boy with a severe form of epidermolysis bullosa.

How close – or far – are we from treating such genetic conditions?

I began my career studying genetic diseases and made the decision, literally on the spot, that I was going to focus on gene therapy. Of course, I didn’t realize at the time how complicated that would be, or how long it would take to get to a point where we were having an impact on patients! It’s been a 30-year journey, and now we’re at the point where we’re seeing gene therapies being approved for patients with rare diseases.

The fact is that we’re only at the beginning, and I have to remind myself – and those who are affected by what we do – that this still experimental science. But we’re at the stage where the translational investigator can play a key role. We’re taking our discoveries from the bench to the bedside, but the most important step in the entire process is learning the potential and limitations of our technology in the clinic, and bringing it back to the bench. The future is bright, and there will be successes, but there will also be failures. One thing is certain: we need to continue to innovate.

My dream since I was a young student has been to change the course for patients with genetic disease.

Your work sounds challenging – but also rewarding...

One thing that I enjoy about my job is the challenge of integrating medicine and science on a daily basis. I find it helpful to view myself as a bit of a generalist, both in terms of clinical practice and research. I try not to stay confined to the disciplines I’ve trained in. I’ve also been able to benefit greatly from the input of the incredibly bright and talented young scientists and trainees in my lab, who help me to expand my horizons.

A critical factor for success is the ability to appreciate the other aspects of translational medicine that you need to move into the clinic – the ones that are not necessarily related to the science. You need to figure out what they are, learn about them, and take as much control over them as you can. For example, interfacing with the biopharmaceutical industry, and the various aspects of technology transfer. I often see scientists defer these important parts of the process to others. Learning what these issues are and getting involved has given me more influence and control over the trajectory of my work, and that has been pivotal to my success.

What advice would you give to young translational researchers?

There are three areas to consider. The first is to establish a goal, and do whatever you need to do to achieve it. Also you must realize that you may be forced to become knowledgeable about (or even a master in) areas of science or medicine that you previously had no direct experience of.

Secondly – and crucially – place yourself in an environment that is truly committed to translational research. I see the word translation virtually everywhere, but very few institutions really support the development of careers in translational research, or support bench to bedside and first-in-human studies, which is where our impact can be. Find that institution, and get there.

Finally, our field is complicated, and involves many different stakeholders and contributors. As a translational scientist, you can be the glue that brings them all together – the “missing link.” So you have to be interested in networking and building teams. You need to be a leader, and pull together many diverse individuals, many of whom don’t report to you. It’s a real skill, but essential for your success.

What is your career highlight?

I still think I’m waiting for the true highlight. My dream since I was a young student has been to change the course for patients with genetic disease, and I think we’re getting closer and closer. These families had no hope, but now I think we’re providing a little. We want to go further by providing real solutions.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine